How Long Does Xolair Take to Work for Chronic Urticaria?
At a Glance
For chronic spontaneous urticaria, Xolair (omalizumab) may begin helping within days, but many people need several weeks to months. In trials, the median time was about 6 weeks for well-controlled hives and 12–13 weeks for no hives or itch; responses vary.
In this answer
3 sections
If you are starting Xolair (omalizumab) for chronic spontaneous urticaria (CSU), you are likely eager for relief. Waiting through ongoing itching and unpredictable flares can be exhausting, but it helps to know what to expect.
For some people, Xolair begins working within a few days, but for most, it takes several weeks to a few months to see the full benefits. In clinical trials, the median time (the point where half of the patients saw this result) to get hives well-controlled was about 6 weeks, and the median time to achieve a “complete response” was about 12 to 13 weeks [1]. A complete response means having no hives and no itch during a measured 7-day period—it does not mean the condition is permanently cured, as symptoms can return if treatment is stopped [1][2].
Because biologics are typically used as an add-on treatment after antihistamines haven’t worked well enough, it is important to know that your personal timeline depends on the underlying biology of your condition [1].
Important Safety Warning: Anaphylaxis
Xolair carries a rare but serious risk of anaphylaxis (a life-threatening allergic reaction), which can happen immediately or even days after an injection, and can occur after the first dose or later doses. Seek emergency medical care immediately if you experience trouble breathing, swelling of your throat or tongue, faintness, or rapidly worsening symptoms. Follow your clinic’s specific instructions for observation after your injection and for using an epinephrine auto-injector if one was prescribed.
Why Response Times Vary: Research Patterns
Researchers have identified two main underlying patterns (or “endotypes”) of CSU that can influence how quickly someone might respond to Xolair. These are not mutually exclusive, definitive clinical diagnoses, but they help explain why timelines vary:
- Type I (Autoallergic) Pattern: In this pattern, the immune system acts as if it is having an allergic reaction to something within the body. Patients with this pattern often have higher levels of total IgE (an allergy-related antibody) in their blood [3][4]. This pattern is often associated with a faster response to Xolair, sometimes within days or a few weeks [4][5].
- Type IIb (Autoimmune) Pattern: Here, the immune system creates IgG autoantibodies directed against IgE or the high-affinity IgE receptor (FcεRI) on your allergy cells (mast cells and basophils), causing them to activate and release histamine [6][7]. Patients with this pattern often have lower total IgE levels and may have other autoimmune conditions, like autoimmune thyroid disease [6][7]. If your CSU leans toward this pattern, you may have a delayed response, meaning it could take several months of monthly injections to see your hives improve, or you might only achieve a partial response [8][9][7].
Keep in mind that no single blood test—including total IgE—can perfectly predict your individual timeline or determine your dose [10][8].
Tracking Your Progress with the UAS7
While waiting for Xolair to take full effect, it is critical to track your symptoms. The standard tool is the UAS7 (Urticaria Activity Score over 7 days).
The UAS7 is a daily diary where you rate your itch and hives on a scale of 0 to 3 each day.
- Hives (Wheals): 0 (none), 1 (less than 20), 2 (20 to 50), 3 (more than 50 or large hives)
- Itch: 0 (none), 1 (mild), 2 (moderate), 3 (severe)
At the end of the week, you add up your daily scores for a total weekly score between 0 and 42 [11][12].
- 0: Urticaria-free (no hives or itch)
- 1–6: Well-controlled hives
- 7–15: Mild symptoms
- 16–27: Moderate symptoms
- 28–42: Severe symptoms [13][2]
Limitation of the UAS7: The UAS7 only measures hives and itch. It does not capture angioedema (deep swelling of the lips, eyelids, or tongue), sleep disruption, or the impact on your daily life [14][15]. You could have a UAS7 of 0 but still experience significant swelling. If you have angioedema, track it separately and share that information with your doctor.
What to Expect at Your Follow-Up
Clinicians typically evaluate how well Xolair is working around the 3-month mark (usually after 3 injections) [16][17].
- If your UAS7 score has dropped (a 10- or 11-point drop is generally a meaningful improvement) or your hives are improving, your doctor will likely recommend continuing the injections, as partial responders often continue to improve over 3 to 6 months [16][17][18].
- If you have seen absolutely no improvement after an appropriate trial of 1 to 3 months, your doctor may reassess your diagnosis or discuss adjusting your overall treatment plan [17].
Do not stop or alter your injections without talking to your prescriber, and remember to keep taking any prescribed daily antihistamines while waiting for Xolair to work, unless your doctor tells you otherwise [2].
Common questions in this guide
How quickly can Xolair improve chronic hives?
What if Xolair has not helped after my first few injections?
How can I track whether Xolair is helping my hives?
Can a blood test predict how fast Xolair will work?
Will my chronic hives come back if I stop Xolair?
Should I keep taking antihistamines while waiting for Xolair to work?
Which symptoms after a Xolair injection require emergency care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Based on my overall clinical picture, is there any blood work that might help set my expectations for how quickly I will respond to Xolair?
- 2.At what specific point in my treatment timeline will we officially evaluate if Xolair is working for me?
- 3.If I only see a partial improvement by our evaluation date, what are our options for adjusting my treatment plan?
- 4.How should I track and report my angioedema (swelling) episodes, since the UAS7 only measures hives and itch?
- 5.Which specific symptoms should prompt me to seek urgent or emergency care after an injection?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (18)
- 1
Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
Kaplan A, Ferrer M, Bernstein JA, et al.
The Journal of allergy and clinical immunology 2016; (137(2)):474-81.
PMID: 26483177 - 2
Management of chronic spontaneous urticaria (CSU): a treat to target approach using a patient reported outcome.
Lima H, Gooderham M, Dutz J, et al.
Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2017; (13()):38 doi:10.1186/s13223-017-0210-0.
PMID: 28852410 - 3
Biomarkers of Autoimmune Chronic Spontaneous Urticaria.
Larenas-Linnemann D
Current allergy and asthma reports 2023; (23(12)):655-664 doi:10.1007/s11882-023-01117-7.
PMID: 38064133 - 4
Omalizumab for the Treatment of Chronic Spontaneous Urticaria in Adults and Adolescents: An Eight-Year Real-Life Experience.
Calzari P, Chiei Gallo A, Barei F, et al.
Journal of clinical medicine 2024; (13(18)) doi:10.3390/jcm13185610.
PMID: 39337097 - 5
Chronic Spontaneous Urticaria: A Review.
Kolkhir P, Bonnekoh H, Metz M, Maurer M
JAMA 2024; (332(17)):1464-1477 doi:10.1001/jama.2024.15568.
PMID: 39325444 - 6
Biomarkers and clinical characteristics of autoimmune chronic spontaneous urticaria: Results of the PURIST Study.
Schoepke N, Asero R, Ellrich A, et al.
Allergy 2019; (74(12)):2427-2436 doi:10.1111/all.13949.
PMID: 31228881 - 7
The autologous serum skin test predicts the response to anti-IgE treatment in chronic spontaneous urticaria patients: a prospective study.
Palladino A, Villani F, Pinter E, et al.
European annals of allergy and clinical immunology 2025; (57(3)):115-119 doi:10.23822/EurAnnACI.1764-1489.337.
PMID: 38482859 - 8
Biopredictors for Omalizumab Response in Patients With Chronic Spontaneous Urticaria.
Le M, McCaffrey T, Gao L, Saini S
The journal of allergy and clinical immunology. In practice 2026; (14(2)):495-502.e1 doi:10.1016/j.jaip.2025.11.029.
PMID: 41319902 - 9
Autoimmune chronic spontaneous urticaria.
Kolkhir P, Muñoz M, Asero R, et al.
The Journal of allergy and clinical immunology 2022; (149(6)):1819-1831 doi:10.1016/j.jaci.2022.04.010.
PMID: 35667749 - 10
Predictors of response to omalizumab and relapse in chronic spontaneous Urticaria: a narrative review focusing on parameters available in routine clinical practice.
Mateu-Arrom L, Vence Nogueira XA, Puig L, Spertino J
Frontiers in allergy 2025; (6()):1688464 doi:10.3389/falgy.2025.1688464.
PMID: 41246132 - 11
The Urticaria Activity Score-Validity, Reliability, and Responsiveness.
Hawro T, Ohanyan T, Schoepke N, et al.
The journal of allergy and clinical immunology. In practice 2018; (6(4)):1185-1190.e1 doi:10.1016/j.jaip.2017.10.001.
PMID: 29128337 - 12
Comparison of Urticaria Activity Score Over 7 Days (UAS7) Values Obtained from Once-Daily and Twice-Daily Versions: Results from the ASSURE-CSU Study.
Hollis K, Proctor C, McBride D, et al.
American journal of clinical dermatology 2018; (19(2)):267-274 doi:10.1007/s40257-017-0331-8.
PMID: 29368043 - 13
EQ-5D Utilities in Chronic Spontaneous/Idiopathic Urticaria.
Hawe E, McBride D, Balp MM, et al.
PharmacoEconomics 2016; (34(5)):521-7 doi:10.1007/s40273-015-0375-7.
PMID: 26792790 - 14
Analysis of disease activity categories in chronic spontaneous/idiopathic urticaria.
Stull D, McBride D, Tian H, et al.
The British journal of dermatology 2017; (177(4)):1093-1101 doi:10.1111/bjd.15454.
PMID: 28295198 - 15
Correlation of disease activity (Urticaria Activity Score over 7 Days) and quality of life (Chronic Urticaria Quality of Life Questionnaire) in patients with chronic spontaneous urticaria: A prospective observational study.
Dash M, Ayub A, Vasudevan B, Sood A
Allergy and asthma proceedings 2026; (47(4)):e57-e64 doi:10.2500/aap.2026.47.260027.
PMID: 42343500 - 16
Expert opinion: defining response to omalizumab in patients with chronic spontaneous urticaria.
Ferrer M, Boccon-Gibod I, Gonçalo M, et al.
European journal of dermatology : EJD 2017; (27(5)):455-463 doi:10.1684/ejd.2017.3085.
PMID: 29084635 - 17
Algorithm for Treatment of Chronic Spontaneous Urticaria with Omalizumab.
Spertino J, Curto Barredo L, Rozas Muñoz E, et al.
Actas dermo-sifiliograficas 2018; (109(9)):771-776 doi:10.1016/j.ad.2018.07.005.
PMID: 30107875 - 18
The minimal important difference for measures of urticaria disease activity: Updated findings.
Mathias SD, Crosby RD, Rosén KE, Zazzali JL
Allergy and asthma proceedings 2015; (36(5)):394-8 doi:10.2500/aap.2015.36.3873.
PMID: 26314821
This page describes expected Xolair response times for chronic urticaria for informational purposes only and does not constitute medical advice. Follow your prescriber's instructions and seek emergency care for possible anaphylaxis.
Get notified when new evidence is published on chronic idiopathic urticaria.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.